Idiopathic vitritis in the setting of Boston keratoprosthesis

Cornea

Volumn 34, Issue 2, 2015, Pages 165-170

  Grassi, Christina M ^a   Crnej, Alja ^a   Paschalis, Eleftherios I ^a   Colby, Kathryn A ^a   Dohlman, Claes H ^a   Chodosh, James ^a  

^a MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

Author keywords

Complications; Keratoprosthesis; Vitritis

Indexed keywords

CORTICOSTEROID; PREDNISOLONE ACETATE; QUINOLONE DERIVATIVE; TRIAMCINOLONE;

ADULT; AGED; ARTICLE; BOSTON KERATOPROSTHESIS; CONVALESCENCE; CORTICOSTEROID THERAPY; ENDOPHTHALMITIS; FEMALE; HUMAN; IDIOPATHIC VITRITIS; KERATOPROSTHESIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT INDICATION; VISUAL ACUITY; VISUAL ACUITY CHART; VISUAL IMPAIRMENT; VITRITIS; ARTIFICIAL ORGAN; CORNEA; CORNEAL DISEASES; EYE DISEASES; INFLAMMATION; MIDDLE AGED; PATHOLOGY; POSTOPERATIVE COMPLICATION; PROSTHESES AND ORTHOSES; VERY ELDERLY; VITREOUS BODY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ARTIFICIAL ORGANS; CORNEA; CORNEAL DISEASES; EYE DISEASES; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROSTHESES AND IMPLANTS; RETROSPECTIVE STUDIES; VITREOUS BODY; YOUNG ADULT;

EID: 84925801338     PISSN: 02773740     EISSN: 15364798     Source Type: Journal    
DOI: 10.1097/ICO.0000000000000328     Document Type: Article

References (36)

1. World Health Organization. Causes of blindness and visual Impairment. Available at: http://www.who.int/blindness/causes/en/. Accessed September 7, 2014.
2. Aquavella JV, Rao GN, Brown AC, et al. Results, complications, and management. Ophthalmology. 1982;89:655-660.
3. Dohlman CH, Harissi-Dagher M, Khan BF, et al. Introduction to the Use of the Boston Keratoprosthesis. Expert Rev Ophthalmol. 2006;1:41-48.
4. Zerbe BL, Belin MW, Ciolino JB, et al. Results from the multicenter Boston type 1 keratoprosthesis study. Ophthalmology. 2006;113:1779-1784.
5. Todani A, Ciolino JB, Ament JD, et al. Titanium back plate for a PMMA keratoprosthesis: clinical outcomes. Graefes Arch Clin Exp Ophthalmol. 2011;249:1515-1518.
6. Doane MG, Dohlman CH, Bearse G. Fabrication of a keratoprosthesis. Cornea. 1996;15:179-184.
7. Traish AS, Chodosh J. Expanding application of the boston type I keratoprosthesis due to advances in design and improved post-operative therapeutic strategies. Semin Ophthalmol. 2010;25:239-243.
8. Aldave AJ, Kamal KM, Vo RC, et al. The Boston type I keratoprosthesis: improving outcomes and expanding indications. Ophthalmology. 2009;116:640-651.
9. Aldave AJ, Sangwan VS, Basu S, et al. International results with the Boston type I keratoprosthesis. Ophthalmology. 2012;119:1530-1538.
10. Bradley JC, Hernandez EG, Schwab IR, et al. Boston type 1 keratoprosthesis: the university of california davis experience. Cornea. 2009;28:321-327.
11. Chew HF, Ayres BD, Hammersmith KM, et al. Boston keratoprosthesis outcomes and complications. Cornea. 2009;28:989-996.
12. Greiner MA, Li JY, Mannis MJ. Longer-term vision outcomes and complications with the Boston type 1 keratoprosthesis at the University of California, Davis. Ophthalmology. 2011;118:1543-1550.
13. Panarelli JF, Ko A, Sidoti PA, et al. Angle closure after Boston keratoprosthesis. J Glaucoma. 2013;22:725-729.
14. Ciolino JB, Belin MW, Todani A, et al. Retention of the Boston keratoprosthesis type 1: multicenter study results. Ophthalmology. 2013;120:1195-1200.
15. Nouri M, Durand ML, Dohlman CH. Sudden reversible vitritis after keratoprosthesis: an immune phenomenon? Cornea. 2005;24:915-919.
16. Schulze-Bonsel K, Feltgen N, Burau H, et al. Visual acuities "hand motion" and "counting fingers" can be quantified with the freiburg visual acuity test. Invest Ophthalmol Vis Sci. 2006;47:1236-1240.
17. Holladay JT. Proper method for calculating average visual acuity. J Refract Surg. 1997;13:388-391.
18. Rosser DA, Cousens SN, Murdoch IE, et al. How sensitive to clinical change are ETDRS logMAR visual acuity measurements? Invest Ophthalmol Vis Sci. 2003;44:3278-3281.
19. Yaghouti F, Nouri M, Abad JC, et al. Keratoprosthesis: preoperative prognostic categories. Cornea. 2001;20:19-23.
20. Chan CC, Holland EJ. Infectious endophthalmitis after Boston type 1 keratoprosthesis implantation. Cornea. 2012;31:346-349.
21. Chan CC, Holland EJ. Infectious keratitis after Boston type 1 keratoprosthesis implantation. Cornea. 2012;31:1128-1134.
22. Utine CA, Tzu JH, Akpek EK. Clinical features and prognosis of Boston type I keratoprosthesis-associated corneal melt. Ocul Immunol Inflamm. 2011;19:413-418.
23. Kang JJ, de la Cruz J, Cortina MS. Visual outcomes of Boston keratoprosthesis implantation as the primary penetrating corneal procedure. Cornea. 2012;31:1436-1440.
24. Nguyen AM, Rao NA. Oxidative photoreceptor cell damage in autoimmune uveitis. J Ophthalmic Inflamm Infect. 2011;1:7-13.
25. Beer PM, Bakri SJ, Singh RJ, et al. Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology. 2003;110:681-686.
26. Campochiaro PA, Hafiz G, Shah SM, et al. Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert. Ophthalmology. 2010;117:1393-1393.e3.
27. Sayegh RR, Ang LP, Foster CS, et al. The Boston keratoprosthesis in Stevens-Johnson syndrome. Am J Ophthalmol. 2008;145:438-444.
28. Iyer G, Pillai VS, Srinivasan B, et al. Modified osteo-odonto keratoprosthesis-the Indian experience-results of the first 50 cases. Cornea. 2010;29:771-776.
29. Huang Y, Yu J, Liu L, et al. Moscow eye microsurgery complex in Russia keratoprosthesis in Beijing. Ophthalmology. 2011;118:41-46.
30. Huang Y, Dong Y, Wang L, et al. Long-term outcomes of MICOF keratoprosthesis in the end stage of autoimmune dry eyes: an experience in China. Br J Ophthalmol. 2012;96:28-33.
31. Clark WL, Kaiser PK, Flynn HW, et al. Treatment strategies and visual acuity outcomes in chronic postoperative Propionibacterium acnes endophthalmitis. Ophthalmology. 1999;106:1665-1670.
32. Streilein JW, Ksander BR, Taylor AW. Immune deviation in relation to ocular immune privilege. J Immunol. 1997;158:3557-3560.
33. Ray S, Khan BF, Dohlman CH, et al. Management of vitreoretinal complications in eyes with permanent keratoprosthesis. Arch Ophthalmol. 2002;120:559-566.
34. Durand ML, Dohlman CH. Successful prevention of bacterial endophthalmitis in eyes with the Boston keratoprosthesis. Cornea. 2009;28:896-901.
35. Ramchandran RS, Diloreto DA, Chung MM, et al. Infectious endophthalmitis in adult eyes receiving Boston type I keratoprosthesis. Ophthalmology. 2012;119:674-681.
36. Robert MC, Moussally K, Harissi-Dagher M. Review of endophthalmitis following Boston keratoprosthesis type 1. Br J Ophthalmol. 2012;96:776-780.